Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Head & Neck 1

Conditions

Glioblastoma 6Diffuse Intrinsic Pontine Glioma 3Recurrence 2Glioma 2Brain Neoplasms 2Central Nervous System Neoplasms 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 23Bevacizumab 18Cyclophosphamide 9Carboplatin 7Lomustine 6Irinotecan 63-Iodobenzylguanidine 6Topotecan 5Radiotherapy 5Filgrastim 5Radiosurgery 4Nivolumab 4Everolimus 4Etoposide 4Drug Therapy 4Busulfan 4sonidegib 3pembrolizumab 3olaparib 3fludarabine phosphate 3fludarabine 3cemiplimab 3antineoplaston AS 2-1 3antineoplaston A10 3Vincristine 3Thiotepa 3Sirolimus 3Melphalan 3IL13-PE38 3Antilymphocyte Serum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Re-Irradiation × CNS × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

NCT01469247 2022-10-20

Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)

M.D. Anderson Cancer Center

Phase 1/2 Completed
12 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡